A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

To join this study, you need to be an adult with an advanced solid tumour that has spread or is difficult to treat. Your cancer must have specific genetic changes called BRAF Class I, Class II, Class III, or, if you have melanoma, an NRAS mutation. These changes must have been found in a previous genetic test of your tumour.

You also need to be well enough to take part, meaning you can swallow and digest medicines by mouth, and your organs (like your liver and kidneys) are working well. Your doctor will check this, along with how active you are in your daily life. The cancer must also be measurable, meaning doctors can see and track its size.

There are some reasons why you might not be able to join. For example, if you've recently had surgery or radiotherapy for your cancer (though some people with brain tumours might still be eligible). You can't have had certain other targeted cancer treatments if you're joining the second part of the study. You also wouldn't be able to join if you have certain gut problems, an active serious infection (including COVID-19), or if you are pregnant or breastfeeding, or have another active cancer that has been treated in the past three years.

If you decide to take part, you will be taking a study medicine, KIN-2787, which comes as a tablet that you swallow. Depending on which part of the study you are in, you might take KIN-2787 alone or together with another tablet, binimetinib. You will have regular visits to the clinic for checks and assessments, which will include blood tests, scans to check your cancer, and discussions about how you are feeling and any side effects. The visits will be more frequent at the beginning of the study. The total duration of your participation will depend on how you respond to the treatment and should be discussed with the study team.